View Cart  

EC: Scrutiny Leads to Decline in ‘Problematic’ Patent Deals

A A
The number of patent settlements between brand- and generic-drug makers considered by the European Commission (EC) to be “potentially problematic” has fallen since the commission increased its scrutiny of the deals, a new report says.

To View This Article:

Login

Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $10.00